Abstract
Sulindac sulfide (SS), the active metabolite of the colon cancer chemopreventive compound sulindac, inhibits the proliferation of HT-29 colon cancer cells mainly by inducing cell quiescence. We determined by bivariate flow-cytometric analysis both the DNA and cyclin protein content of individual cells. Thus, we assessed in detail the expression of several cyclins during the cell-cycle phases and demonstrated that SS (i) decreases the expression of cyclins B1 and E and (ii) increases the expression of cyclins D1, D2 and D3, particularly in the G1 phase of the cell cycle. SS-induced apoptotic cells expressed both E- and D-type cyclins but not cyclin B1. The changes in cyclin expression combined with reduced catalytic activity of cyclin-dependent kinases could explain in molecular terms the anti-proliferative effect of SS on HT-29 colon cancer cells. These changes may contribute to the chemopreventive effect of sulindac.
References
Sep 1, 1983·Journal of Surgical Oncology·W R Waddell, R W Loughry
Jul 4, 1995·International Journal of Cancer. Journal International Du Cancer·K KitaharaE Tahara
Jul 1, 1995·The Journal of Clinical Investigation·S J ShiffB Rigas
Jun 1, 1995·Cell Proliferation·J GongZ Darzynkiewicz
Apr 1, 1995·Seminars in Cancer Biology·J Pines
Apr 1, 1995·Seminars in Cancer Biology·S Bates, G Peters
Mar 9, 1995·Nature·D O Morgan
Nov 18, 1994·Cell·C J Sherr
Aug 15, 1994·Annals of Internal Medicine·E GiovannucciW C Willett
May 6, 1993·The New England Journal of Medicine·F M GiardielloG J Offerhaus
Feb 17, 1993·Journal of the National Cancer Institute·G GridleyJ F Fraumeni
Jun 18, 1993·Cell·C J Sherr
Jan 10, 1996·Experimental Cell Research·S J ShiffB Rigas
Jan 1, 1996·Journal of Cancer Research and Clinical Oncology·A WangH Mori
Mar 1, 1996·Gastroenterology·N ArberP R Holt
Jun 11, 1996·Proceedings of the National Academy of Sciences of the United States of America·J B SchnierE M Bradbury
Jul 26, 1996·Biochemical Pharmacology·R HanifB Rigas
Oct 1, 1996·Molecular and Cellular Biology·R U JänickeA G Porter
May 19, 1997·Cancer Letters·L QiaoB Rigas
Citations
May 24, 2008·Carcinogenesis·Hector Guillen-AhlersVictoria A Ploplis
Nov 27, 2002·Cancer Investigation·Yaser RayyanBasil Rigas
Feb 5, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Nuria A CallejasPaloma Martín-Sanz
Oct 25, 2003·Pancreas·Michele T Yip-Schneider, C Max Schmidt
Nov 15, 2000·Critical Reviews in Clinical Laboratory Sciences·E Fosslien
Jul 1, 2005·Digestive Diseases and Sciences·Hassan AshktorabDuane T Smoot
Nov 20, 2002·The Journal of Pharmacology and Experimental Therapeutics·Khosrow KashfiYassir Ryann
Sep 10, 1999·The Journal of Biological Chemistry·Y YamamotoR B Gaynor
Oct 19, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·S GröschG Geisslinger
Aug 3, 2002·Journal of Neuropathology and Experimental Neurology·Jeroen J M HoozemansThomas Arendt
May 3, 2000·Medical Hypotheses·B Rigas, S J Shiff
May 18, 2021·Genes & Diseases·Hongyou ZhaoYaguang Xi
Jun 14, 2005·Biochemical Pharmacology·Khosrow Kashfi, Basil Rigas